Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation

被引：23
|
作者：
Ru, Yuhua [1 ,2 ]
Chen, Jia [1 ,2 ]
Wu, Depei [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou 215006, Peoples R China
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 03期
基金：
美国国家科学基金会; 国家重点研发计划;
关键词：
EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease; BONE-MARROW-TRANSPLANTATION; EBV REACTIVATION; RISK-FACTORS; VIRAL LOAD; PREEMPTIVE RITUXIMAB; PROLONGED HYPOGAMMAGLOBULINEMIA; ALLOGENEIC TRANSPLANTATION; HEART-TRANSPLANTATION; EUROPEAN CONFERENCE; PEDIATRIC-PATIENTS;
D O I：
10.1111/ejh.13131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
引用
收藏
页码：283 / 290
页数：8
相关论文
共 50 条
  • [1] Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
    Liu, Li
    Liu, Qifa
    Feng, Sizhou
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [2] Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation
    Lindsay, Julian
    Yong, Michelle K.
    Greenwood, Matthew
    Kong, David C. M.
    Chen, Sharon C. A.
    Rawlinson, William
    Slavin, Monica
    REVIEWS IN MEDICAL VIROLOGY, 2020, 30 (04)
  • [3] Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant
    Rouce, Rayne H.
    Louis, Chrystal U.
    Heslop, Helen E.
    CURRENT OPINION IN HEMATOLOGY, 2014, 21 (06) : 476 - 481
  • [4] Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation
    Feuillet, S.
    Meignin, V.
    Briere, J.
    Brice, P.
    Rocha, V.
    Socie, G.
    Tazi, A.
    Bergeron, A.
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2009, 2 : 11 - 15
  • [5] Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes
    Fujimoto, Ayumi
    Suzuki, Ritsuro
    CANCERS, 2020, 12 (02)
  • [6] Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
    Liu, Li
    Zhang, Xuyan
    Feng, Sizhou
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1341 - 1349
  • [7] Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder
    Kalra, Amit
    Roessner, Cameron
    Jupp, Jennifer
    Williamson, Tyler
    Tellier, Raymond
    Chaudhry, Ahsan
    Khan, Faisal
    Taparia, Minakshi
    Jimenez-Zepeda, Victor H.
    Stewart, Douglas A.
    Daly, Andrew
    Storek, Jan
    CYTOTHERAPY, 2018, 20 (05) : 706 - 714
  • [8] Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation
    Kim, Bo Kyung
    Kang, Hyoung Jin
    Hong, Kyung Taek
    An, Hong Yul
    Choi, Jung Yoon
    Lee, Jee Soo
    Park, Sung Sup
    Shin, Hee Young
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (06)
  • [9] Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
    Ali, Salah
    AlThubaiti, Sami
    Renzi, Samuele
    Krueger, Joerg
    Chiang, K. Y.
    Naqvi, Ahmed
    Schechter, Tal
    Punnett, Angela
    Ali, Muhammad
    PEDIATRIC TRANSPLANTATION, 2019, 23 (01)
  • [10] Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
    Clerico, Michele
    Dogliotti, Irene
    Aroldi, Andrea
    Consoli, Chiara
    Giaccone, Luisa
    Bruno, Benedetto
    Cavallo, Federica
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
12345